StreetInsider.com News Articles

Keenova Champions Men's Health Month with Education and Outreach

Mon, 01 Jun 2026 16:15:00 -0400

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

DUBLIN, June 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health by hosting a Reddit "Ask Me Anything" (AMA) focused on Peyronie's disease and launching a new provider intake tool designed to support conversations about sensitive health conditions.

Keenova Champions Men's Health Month with Education and Outreach

Mon, 01 Jun 2026 16:15:00 -0400

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Fri, 15 May 2026 07:36:00 -0400

DUBLIN, May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX^® (collagenase clostridium histolyticum) will be shared at the American Urological Association (AUA) annual meeting, taking place May 15–18, 2026. The data to be presented will highlight that the clinical effectiveness and safety of XIAFLEX (collagenase clostridium histolyticum) in patients with ventral curvature are consistent with outcomes observed in patients with other clinical presentations of Peyronie's disease.

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Fri, 15 May 2026 07:36:00 -0400

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking

Mon, 04 May 2026 07:30:00 -0400

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

DUBLIN, May 4, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today the launch of its newest television commercial and disease awareness campaign, Don't Be a Viking.